Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens - PubMed (original) (raw)
Comparative Study
Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens
T S Barry et al. J Exp Med. 1991.
Abstract
To develop a model of human thymus growth in vivo, we have implanted postnatal human thymus under the renal capsule of severe combined immune deficient (SCID) mice and assayed for graft survival and graft characteristics 1-3 mo after engraftment. Three groups of SCID mice were engrafted with postnatal human thymus: untreated SCID mice, SCID mice pretreated with 400 cGy of gamma irradiation 1-5 d before engraftment, and SCID mice treated with intraperitoneal anti-asialo GM-1 antiserum every 4-5 d during engraftment. In the untreated group of SCID mice, only 37% of grafts survived and consisted of human thymic microenvironment components and human immature thymocytes. Irradiation of SCID mice before engraftment improved survival of human thymic grafts to 83%, but these grafts were largely devoid of thymocytes and contained only thymic microenvironment components with large numbers of thymic macrophages. Treatment of SCID mice with anti-asialo GM-1 antiserum throughout the engraftment period also promoted human thymus engraftment (70%) and induced SCID B cell Ig production (SCID[Ig+]) in 38% of animals. In SCID(Ig-) anti-asialo GM-1-treated mice, the human thymic grafts were similar in content to those in untreated SCID mice. However, in anti-asialo GM-1-treated animals with grafts that became SCID(Ig+), all animals were found to have mouse-human chimeric grafts in that the human thymic microenvironment (human fibroblasts, thymic epithelium, vessels) was colonized by murine T cells. These data demonstrate that human postnatal thymus will grow as xenografts in SCID mice, and that the components of human thymus that engraft are dependent on the immunosuppressive regimen used in recipient mice. A striking finding in this study was the induction of T and B lymphopoiesis in SCID mice by abrogation of NK cell activity with in vivo anti-asialo GM-1 treatment. These data strongly suggest that asialo GM-1+ NK cells and/or macrophages play a role in mediation of suppression of lymphopoiesis in SCID mice.
Similar articles
- A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M, Brown SA, Tutt LM, Tan J, Seehafer DL, Harris JP, Xun CQ, Thompson JS. Tsuchida M, et al. Clin Transplant. 1997 Oct;11(5 Pt 2):522-8. Clin Transplant. 1997. PMID: 9361954 - Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice.
Yoshino H, Ueda T, Kawahata M, Kobayashi K, Ebihara Y, Manabe A, Tanaka R, Ito M, Asano S, Nakahata T, Tsuji K. Yoshino H, et al. Bone Marrow Transplant. 2000 Dec;26(11):1211-6. doi: 10.1038/sj.bmt.1702702. Bone Marrow Transplant. 2000. PMID: 11149733 - High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1.
Shpitz B, Chambers CA, Singhal AB, Hozumi N, Fernandes BJ, Roifman CM, Weiner LM, Roder JC, Gallinger S. Shpitz B, et al. J Immunol Methods. 1994 Feb 28;169(1):1-15. doi: 10.1016/0022-1759(94)90119-8. J Immunol Methods. 1994. PMID: 7907638 - Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review. - Human T lymphopoiesis. In vitro and in vivo study models.
Plum J, De Smedt M, Verhasselt B, Kerre T, Vanhecke D, Vandekerckhove B, Leclercq G. Plum J, et al. Ann N Y Acad Sci. 2000;917:724-31. doi: 10.1111/j.1749-6632.2000.tb05436.x. Ann N Y Acad Sci. 2000. PMID: 11268400 Review.
Cited by
- Potential of the scid mouse as a host for human tumors.
Mueller BM, Reisfeld RA. Mueller BM, et al. Cancer Metastasis Rev. 1991 Oct;10(3):193-200. doi: 10.1007/BF00050791. Cancer Metastasis Rev. 1991. PMID: 1764764 Review. - Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis.
Davis LS, Sackler M, Brezinschek RI, Lightfoot E, Bailey JL, Oppenheimer-Marks N, Lipsky PE. Davis LS, et al. Am J Pathol. 2002 Jan;160(1):357-67. doi: 10.1016/S0002-9440(10)64379-9. Am J Pathol. 2002. PMID: 11786429 Free PMC article. - Development of CD4+CD8+ thymocytes in RAG-deficient mice through a T cell receptor beta chain-independent pathway.
Guidos CJ, Williams CJ, Wu GE, Paige CJ, Danska JS. Guidos CJ, et al. J Exp Med. 1995 Mar 1;181(3):1187-95. doi: 10.1084/jem.181.3.1187. J Exp Med. 1995. PMID: 7869035 Free PMC article. - Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice.
Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Tanaka T, et al. J Exp Med. 1993 Sep 1;178(3):1103-7. doi: 10.1084/jem.178.3.1103. J Exp Med. 1993. PMID: 8350049 Free PMC article. - Humanized Mice for the Evaluation of Novel HIV-1 Therapies.
Abeynaike S, Paust S. Abeynaike S, et al. Front Immunol. 2021 Apr 1;12:636775. doi: 10.3389/fimmu.2021.636775. eCollection 2021. Front Immunol. 2021. PMID: 33868262 Free PMC article. Review.
References
- J Exp Med. 1989 Jul 1;170(1):191-202 - PubMed
- Scand J Immunol. 1986 Jan;23(1):109-18 - PubMed
- Immunol Today. 1988 Apr;9(4):109-13 - PubMed
- Proc Natl Acad Sci U S A. 1989 Oct;86(19):7575-9 - PubMed
- Immunol Today. 1989 Dec;10(12):423-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources